Evidence map›Paper›PMID 26962734›Full record

ArticleThe New England journal of medicine2016

HLA-Incompatible Kidney Transplantation--Worth the Risk?

Lionel P E Rostaing, Paolo Malvezzi

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Aberrant NADNature metabolism · 2021
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Antibody-Mediated Rejection Due to Preexisting versusJournal of the American Society of Nephrology : JASN · 2017
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Lionel P E RostaingFrom Clinique de Néphrologie, Unité de Transplantation Rénale, Centre Hospitalier Universitaire (CHU) Grenoble-Alpes, La Tronche (L.P.E.R., P.M.), and INSERM Unité 563, Federative Structure of Bio-Medical Research of Toulouse, CHU Purpan, and Université Toulouse III Paul Sabatier, Toulouse (L.P.E.R.) - all in France.
Paolo MalvezziFrom Clinique de Néphrologie, Unité de Transplantation Rénale, Centre Hospitalier Universitaire (CHU) Grenoble-Alpes, La Tronche (L.P.E.R., P.M.), and INSERM Unité 563, Federative Structure of Bio-Medical Research of Toulouse, CHU Purpan, and Université Toulouse III Paul Sabatier, Toulouse (L.P.E.R.) - all in France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HistocompatibilityKidney TransplantationLiving DonorsHumans

Identifiers

PMID26962734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.